874 results about "Gut flora" patented technology

The invention belongs to the technical field of medical data processing and artificial intelligence, and particularly relates to a cardiovascular disease risk prediction system based on multi-modal fusion, which comprises a multi-modal data acquisition and preprocessing module, a cross-modal association graph construction module, a dynamic fusion and prediction module based on a graph neural network and an interpretability analysis module. By constructing a heterogeneous graph fusing prior knowledge and data driving and utilizing a graph attention network to perform multi-level dynamic feature fusion, deep integration and interaction of multi-modal data such as genomes, iconography, clinical and intestinal flora metabolism are realized, so that the accuracy and interpretability of cardiovascular disease risk prediction are improved.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses a method and system for predicting juvenile depression based on intestinal flora, and relates to the technical field of bioinformatics and artificial intelligence, and the method comprises the steps: firstly, obtaining an original sequence of a microbiome, carrying out the preprocessing of the original sequence of the microbiome, and obtaining a feature matrix; and screening core flora characteristics with stable trans-folding by adopting characteristic importance evaluation and interpretability analysis based on a gradient boosting decision tree. A mixed weighted graph is constructed based on Spearman correlation and a proximity relationship, and an absolute value of a correlation coefficient is taken as an edge weight and an edge density is adjusted through a threshold adaptive strategy. And finally, through an improved graph attention neural network, based on edge weight attention, layer normalization and random inactivation, enhancing robustness, and adopting adaptive optimization to complete parameter learning. And determining a dynamic classification threshold according to the AUC of the target patient, and outputting a sample discrimination result and confidence. According to the method, the accuracy, stability and biological interpretability of juvenile depression recognition are remarkably improved.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The invention discloses an application of pleurotus eryngii purified polysaccharide in preparation of an intestinal care medicine. The pleurotus eryngii purified polysaccharide component has high immunocompetence, high-activity and high-purity polysaccharide is obtained after ethanol precipitation and organic solvent purification, and the high biological activity of the polysaccharide is reserved; the composition has the biological activity of increasing the production of short-chain fatty acid, reducing the inflammation level, improving the intestinal flora structure, influencing the body metabolism condition and protecting the intestinal barrier. Compared with other components in the pleurotus eryngii polysaccharide extraction process, the polysaccharide component obtained by the preparation method has the highest purity and the strongest biological activity, and can be used for preparing intestinal care medicines.

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention relates to the technical field of critical nutrition medical treatment, and discloses a critical patient enteral nutrition diarrhea risk prediction model system. A nutrition parameter acquisition module of the system is used for acquiring enteral nutrition formula parameters, including nutrient solution osmotic pressure, infusion speed and nutrient solution temperature, of a critical patient; the physiological index analysis module is used for collecting intestinal flora abundance data, serum albumin level and gastrointestinal peristalsis frequency of the critical patient; the risk feature extraction module is used for calculating an intestinal tolerance feature value according to the enteral nutrition formula parameters and the intestinal flora abundance data; and the prediction model construction module is used for constructing a diarrhea risk prediction model based on the intestinal tolerance characteristic value and the serum albumin level. According to the system, comprehensive acquisition and analysis of enteral nutrition related data of critical patients can be realized, objectivity and accuracy of diarrhea risk prediction are improved, and support is provided for clinical enteral nutrition scheme adjustment and diarrhea prevention.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of health evaluation, in particular to a group image health evaluation method and system based on intestinal flora, and the method comprises the steps: collecting intestinal flora samples of a target group through a standardized process, and obtaining microbial sequence information through a high-throughput sequencing technology; microflora diversity characteristics and core flora characteristics are extracted through strain identification and relative abundance analysis, individual flora characteristics are compared with a healthy population reference database, health state scores are calculated, health grades are divided, population health grade distribution is counted, and the population health grade distribution is calculated. And generating a group health evaluation report containing a visual chart and text analysis. According to the method, a complete technical system from sample collection to health strategy making is established, systematic evaluation of the group health state from the perspective of intestinal flora is achieved, and the limitation of a traditional method in group health early evaluation is overcome. The method is suitable for health monitoring of different scales of groups, and provides effective technical support for public health management and health service.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention discloses a fat-reducing and weight-reducing medicinal and edible food and a preparation method thereof, the composition comprises a lotus leaf extract, a Pu'er tea fermentation product, a hovenia dulcis thunb extract, konjac glucomannan, a pepper extract, fermented mulberry leaf powder, a prebiotic compound and oyster peptide, and the invention relates to the technical field of functional food. According to the fat-reducing and weight-reducing medicinal and edible food and the preparation method thereof, efficient fat reduction is realized through a four-dimensional synergistic effect (regulating lipid metabolism, inhibiting fat absorption, promoting energy consumption and improving intestinal flora).

The invention relates to the technical field of food processing, and discloses Lithocarpus litseifolius low-GI biscuits with an intestinal flora regulation function and a preparation method thereof.The preparation method comprises the following specific steps that Lithocarpus litseifolius tender leaves are spread, aired, roasted, rolled and dried and then made into Lithocarpus litseifolius ultra-fine powder with the specific particle size (300-900 meshes) through an ultra-fine crushing technology, and the Lithocarpus litseifolius ultra-fine powder with the specific particle size (300-900 meshes) is prepared into the Lithocarpus litseifolius low-GI biscuits. And then compounding the Lithocarpus litseifolius with wheat flour to prepare the Lithocarpus litseifolius biscuit. The Lithocarpus litseifolius low-GI biscuit prepared by the method is low in GI value, belongs to medium-GI food, overcomes the defects of high glycemic content and low dietary fiber content of traditional biscuits, is unique in taste and balanced in nutrition, can increase the content of short-chain fatty acid SCFAs in intestinal tracts, has the effects of regulating intestinal flora, maintaining blood sugar balance and reducing fat, and can be used for preparing the low-GI biscuit for the Lithocarpus litseifolius low-GI biscuit. The method has a wide prospect and a high market value.

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention provides a bacillus subtilis strain and application thereof, the bacillus subtilis strain is named as bacillus subtilis Ya3.1, is preserved in China General Microbiological Culture Collection Center on July 7, 2025, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35019; the bacillus subtilis Ya3.1 is separated from intestinal tracts of healthy hybrid sturgeons, and can be used as a probiotic additive for aquaculture, especially for sturgeon culture. The bacillus subtilis Ya3.1 provided by the invention has high safety, strong stress resistance and efficient intestinal colonization ability, and can significantly improve the activity of sturgeon intestinal digestive enzymes, improve the growth performance of sturgeons, enhance the non-specific immunity of sturgeons, improve the intestinal flora structure and significantly improve the ability to resist aeromonas bacterial infection; and a special probiotic resource can be provided for sturgeon culture.

The invention discloses a holothurian culture feed additive and a preparation method thereof, and belongs to the technical field of aquaculture. According to the technical scheme, the holothurian culture feed additive comprises the following components in percentage by mass: 45%-55% of fish meal, 2%-3% of butyric acid bacteria, 25%-30% of compound probiotics, 2%-4% of a Chinese herbal medicine extract, 8%-12% of a fermentation substrate, 10%-15% of seaweed meal, 0.5%-1% of vitamin E, 0.5%-1% of selenium yeast and the balance of a carrier, the compound probiotics are composed of lactic acid bacteria, bacillus and photosynthetic bacteria according to the mass ratio of 2: 1: 1; the Chinese herbal medicine extract is a mixture of astragalus polysaccharide and an asarum extract in a mass ratio of 3: 1; through the synergistic effect of the fish meal, the compound probiotics, the Chinese herbal medicine extract and other components, nutrition balance and intestinal flora regulation and control are achieved, the problems of slow growth, intestinal diseases and water quality pollution caused by traditional feed are effectively solved, and the sea cucumber feed has the advantages that the survival rate of sea cucumbers is increased, and the culture benefits are increased.

The invention discloses a method for treating piglet damp-heat diarrhea through multi-omics combined analysis. According to the method, faeces metabonomics, intestinal transcriptomics and intestinal flora 16s analysis are adopted, transcriptome data, metabolome data and intestinal flora data are screened according to a prime difference standard, then transcriptomics of a model group and a control group, faeces metabonomics and intestinal flora are subjected to conjoint analysis, an intersection is taken, and the faeces metabonomics of the model group and the control group, the faeces metabonomics of the model group and the control group and the intestinal flora of the model group and the control group are subjected carrying out conjoint analysis on transcriptomics of the Model group and HQ-M, faeces metabonomics and intestinal flora, and then taking an intersection; the method comprises the following steps of: selecting a plurality of metabolites and florae from a plurality of intestinal florae, respectively obtaining intersections, screening related genes, searching gene FPKM expression quantity in transcriptomics, and screening corresponding metabolites and florae in metabonomics and intestinal florae to obtain a gene-flora-metabolite related network diagram. Multi-omics combined analysis shows that the piglet diarrhea due to damp-heat is mainly manifested by inflammation and glucose and lipid metabolism disorder.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

The invention discloses a multi-layer multi-release metagen composition and application thereof in quickly promoting defecation, lubricating intestinal tracts, relieving intestinal problems such as flatulence, stomachache, diarrhea, constipation, irritable bowel syndrome and inflammatory bowel disease, maintaining intestinal flora balance, repairing intestinal tracts, repairing intestinal mucosa health, relieving dyspepsia and improving gastrointestinal functions.

The invention relates to a biomarker for screening intestinal flora transplantation donors and application of the biomarker. The biomarker comprises intestinal flora and metabolites thereof, the intestinal flora comprises phylum firmicalis, bacteroides and the like, and the metabolites comprise short-chain fatty acid, tryptophan, indole, 5-hydroxytryptamine, lipopolysaccharide and the like. According to the method, the intestinal flora of different crowds is deeply analyzed, the relationship between each related index of the intestinal flora and the intestinal flora transplantation effect is studied, sufficient clinical verification is carried out, a biomarker for screening the intestinal flora transplantation donor is excavated, and a standard for judging whether the intestinal flora transplantation donor is qualified or not is established; and a new method and a new idea are provided for efficiently and accurately screening intestinal flora transplantation donors.

The invention relates to the technical field of prebiotics preparation, and discloses a preparation method of prebiotics applied to reproduced areca catechu, and the preparation method comprises the following steps: carrying out enzyme catalysis reaction on sucrose by adopting fructosyl transferase to prepare fructo-oligosaccharide; according to the method, beta-galactosidase is adopted to carry out enzyme catalysis reaction on lactose, so that galactooligosaccharide is prepared; respectively carrying out decoloration, ion exchange, nanofiltration concentration and spray drying on the candy oligosaccharide and the galactooligosaccharide to obtain powder; the method comprises the following steps: mixing fructo-oligosaccharide powder and galactooligosaccharide powder according to a ratio, and uniformly distributing the mixture in a reproduced areca-nut matrix by adopting a spray-drying blending or low-temperature vacuum mixing mode to form a functional reproduced areca-nut product; according to the invention, low-temperature drying is carried out on the product after blending or vacuum mixing, so that the prebiotic areca nuts are released along with saliva in the chewing process, and are selectively utilized by bifidobacteria and lactic acid bacteria after entering the stomach and intestine, thereby achieving the purposes of regulating intestinal flora and improving the health-care function.

A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.

The invention belongs to the related technical field of pet prescription food products, and particularly relates to a prescription food for pet dogs with acute intestinal inflammation and a preparation method of the prescription food, the prescription food comprises various components such as rice, barley, chicken powder and corn protein powder, and probiotics are self-made and comprise bifidobacterium, lactobacillus acidophilus and lactobacillus casei. The preparation method comprises the steps of quantitative raw material weighing, auxiliary agent grinding, constant-temperature accurate grinding, adding of specific components for accurate grinding again, heat preservation, deodorization and degassing, drop casting forming, cooling, packaging, sealed storage and the like. Compared with the prior art, the prescription food is high in safety, and feeding tests of healthy dogs have no abnormity; clinical cases show that the leucocyte number and the inflammatory factor content of sick dogs can be reduced; the intestinal barrier can be repaired, so that the intestinal mucosa repair is accelerated; intestinal flora can be improved, and the content of short-chain fatty acid in excrement is increased; the nutrition state can be maintained, and the weight loss range of sick dogs is reduced.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention discloses a method for leaching waste lithium battery positive electrode powder by using intestinal flora in a neutral environment, and belongs to the technical field of resource recycling, the method comprises the following steps: step 1, a pretreatment link, the pretreatment link comprises the following process links, and each link has no sequence: (1) preparation of battery powder, (2) acquisition of intestinal flora, and (3) preparation of a culture medium; 2, domesticating the flora; and 3, valuable metal in the waste battery powder is leached out. According to the method, the intestinal flora is applied to the biological leaching of the waste LIBs positive electrode powder, so that the dependence of traditional strong acidophilic bacteria on an extremely low pH condition is broken through, and the environmental harm is greatly reduced; according to the method, inorganic acid does not need to be added, the pH value of a reaction system is stabilized within the nearly neutral range of 7.8-8.2, equipment loss caused by acid etching is reduced, reagent consumption for subsequent metal recovery and neutralization treatment is reduced, and remarkable economic benefits and environmental benefits are achieved.

The invention discloses a probiotic chitosan microsphere and a preparation method thereof, and belongs to the technical field of probiotic embedding, and the method comprises the following steps: dissolving trehalose and L-glutamine in water, suspending lactic acid bacteria in the water, mixing with a chitosan solution to obtain a mixed solution, dropwise adding the mixed solution into a sodium tripolyphosphate solution, and stirring to obtain the probiotic chitosan microsphere. And washing insoluble substances, and performing freeze drying to obtain the probiotic chitosan microspheres. The trehalose and the L-glutamine are used as protective agents and nutrient substances of the probiotics at the same time, can synergistically improve the survival rate of the probiotics, are matched with other components, comprehensively improve the tolerance and activity of the probiotics, and are combined with a specific curing means and freeze drying, so that damage of high temperature to the probiotics can be avoided; the obtained microspheres have good probiotic protection capability, stability and appropriate release performance, can effectively improve the survival rate of the probiotics in storage and application processes, and can better play roles in improving intestinal flora and improving the health level of hosts.